Press Releases
Secukinumab showed superiority over Enbrel®
Novartis announced results from the head-to-head Phase III FIXTURE study showing secukinumab an interleukin-17A inhibitor, was significantly superior to Enbrel in moderate-to-severe plaque psoriasis....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read